Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04448886 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 26, 2020
Last Update Posted : March 25, 2024
|
Sponsor:
Ana C Garrido-Castro, MD
Collaborators:
Merck Sharp & Dohme LLC
Gilead Sciences
Information provided by (Responsible Party):
Ana C Garrido-Castro, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | March 9, 2024 |
| Estimated Study Completion Date : | June 1, 2027 |